Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

NCT ID: NCT05041842

Last Updated: 2025-11-17

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-17
• Study Completion Date: 2026-04-30

Brief Summary

The overall survival of patients with metastatic breast cancer has steadily improved over the past decades, mainly due to advances in systemic treatment. Despite these advances, the development of brain metastases remains a serious and devastating complication that decreases quality of life and increases morbidity and mortality. The HER2CLIMB randomized study demonstrated that adding the investigational drug tucatinib to the standard treatment trastuzumab and capecitabine improved both progression-free survival and overall survival in people diagnosed with human epidermal growth factor 2 (HER2)-positive metastatic breast cancer, previously treated with trastuzumab, pertuzumab, and T-DM1. In patients with brain metastases, the 1-year progression-free survival was 25% in the tucatinib group and 0% in the placebo group.

These results suggest that tucatinib may be a new standard treatment for HER2-positive metastatic disease.

The aim of the non-randomized phase II study, InTTercePT, is to evaluate the effectiveness of adding tucatinib to trastuzumab and pertuzumab in the event of cerebral progression, after the end of local treatment.

Detailed Description

The overall survival of patients with metastatic breast cancer has steadily improved over the past decades, mainly due to advances in systemic treatment. Despite these advances, the development of brain metastases remains a serious and devastating complication that decreases quality of life and increases morbidity and mortality. More than a third of patients with HER2-positive breast cancer develop brain metastases during the course of the disease. For patients with isolated brain progression, local treatment is recommended whenever possible (stereotaxic radiosurgery and / or surgery) as well as the continuation of systemic treatment previously initiated even if the evidence of a benefit is weak.

After local treatment these patients will have a higher risk of progression (cerebral and systemic). Therefore, the question of whether systemic treatment should be continued or changed remains an open question.

In a pooled analysis of two phase 1b studies, patients who continued systemic treatment with tucatinib (in combination with T-DM1 or with trastuzumab and capecitabine) after treatment directed to the central nervous system demonstrated a better prognosis than that of patients who stopped tucatinib.

The HER2CLIMB randomized study demonstrated that adding the investigational drug tucatinib to the standard treatment trastuzumab and capecitabine improved both progression-free survival and overall survival in people diagnosed with HER2-positive metastatic breast cancer, previously treated with trastuzumab, pertuzumab, and T-DM1. In patients with brain metastases, the 1-year progression-free survival was 25% in the tucatinib group and 0% in the placebo group.

These results suggest that tucatinib may be a new standard treatment for HER2-positive metastatic disease.

We anticipate that adding tucatinib to the trastuzumab / pertuzumab regimen will control brain metastases, prolong progression-free survival, and improve patient quality of life.

The aim of the non-randomized phase II study, InTTercePT, is to evaluate the effectiveness of adding tucatinib to trastuzumab and pertuzumab in the event of cerebral progression, after the end of local treatment.

Conditions

Metastatic Breast Cancer With a Isolated Brain Progression

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Tucatinib plus systemic treatment with or without hormone therapy

Addition of tucatinib to the systemic treatment (pertuzumab and trastuzumab) with or without hormone therapy.

Group Type: EXPERIMENTAL

Tucatinib

Intervention Type: DRUG

300 mg orally twice daily

Pertuzumab

Intervention Type: DRUG

Initial loading: 840 mg Maintenance: 420 mg, 3-weekly

Trastuzumab

Intervention Type: DRUG

Intravenous formulation :

Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly

Subcutaneous formulation:

600 mg (fixed dose regardless of patient's body weight), 3-weekly

Hormone therapy

Intervention Type: DRUG

Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)

Pertuzumab/ Trastuzumab

Intervention Type: DRUG

Initial loading:

1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)

Maintenance:

600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly

Interventions

Tucatinib

300 mg orally twice daily

Intervention Type: DRUG

Pertuzumab

Initial loading: 840 mg Maintenance: 420 mg, 3-weekly

Intervention Type: DRUG

Trastuzumab

Intravenous formulation :

Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly

Subcutaneous formulation:

600 mg (fixed dose regardless of patient's body weight), 3-weekly

Intervention Type: DRUG

Hormone therapy

Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)

Intervention Type: DRUG

Pertuzumab/ Trastuzumab

Initial loading:

1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)

Maintenance:

600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly

Intervention Type: DRUG

Other Intervention Names

Perjeta®; Herceptin® or Biosimilar; Phesgo®

Eligibility Criteria

Inclusion Criteria

1. Male or female, Age ≥18;

2. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1;

3. Histologically confirmed HER2 positive breast cancer, with HER2 positive defined by in situ hybridization (ISH), immunohistochemistry (IHC), or fluorescence in situ hybridization (FISH) methodology;

4. Documented isolated brain progression (defined as new or progressive brain metastases with stable or responding systemic disease) under pertuzumab and trastuzumab treatment (with or without taxane) for metastatic disease (There is no limit to the number and size of brain metastasis);

5. Complete local treatment of brain progression (Surgery and/or radiation therapy) should have been completed no more than 12 weeks before inclusion and there is no clinical indication for immediate re-treatment with local therapy in the opinion of the investigator;

6. Able to undergo MRI scanning of the brain;

7. Normal renal function: creatinine <1.5 x upper limit of normal (ULN);

8. Adequate liver function: total bilirubin ≤1.5 ULN (unless documented Gilbert's syndrome); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 ULN (≤5 ULN in the presence of liver metastases);

9. Normal hematological function: Absolute neutrophil count (ANC) ≥1.5 x 10⁹/L; platelets count ≥100 x 10⁹/L; and hemoglobin ≥9.0 g/dL;

10. Adequate cardiac functions, including:

• 12 Lead electrocardiograms (ECG) with normal tracing or non-clinically significant changes that do not require medical intervention
• QT/Corrected QT interval (QTcF) ≤470 msec for woman and ≤450 msec for men (mean of replicate values, correction per institutional standard) on the ECG at the screening visit and a normal kalemia
• Left ventricular ejection fraction (LVEF) ≥50%
• No history of Torsades de Pointes or other symptomatic QTc abnormality

11. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE version 5.0 Grade 1 or to baseline (except alopecia or others toxicities not considered a safety risk for the patient at investigator's discretion);

12. Stable dose of steroids at the time of enrolment;

13. Women of childbearing potential must have a negative pregnancy test (blood or urine test) within 14 days prior to inclusion;

14. Woman of childbearing potential and male patients must agree to use adequate contraception for the duration of trial participation and up to 7 months after completing treatment/therapy (association of trastuzumab, pertuzumab +/- tucatinib). Hormonal contraceptives such as birth control pills, patches, implants, or injections are not allowed in patients who are hormone receptor positive;

15. Patient must have signed a written informed consent form prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent;

16. Patients affiliated to the social security system (or equivalent);

17. Patient must be willing and able to comply with the protocol for the duration of the trial including scheduled visits, treatment plan, laboratory tests, and examinations including follow-up.

Exclusion Criteria

1. Radiologic extra-cranial progression under pertuzumab and trastuzumab treatment, at the time of enrolment. The systemic disease must be stable or responding at the time of enrolment;

2. Proven leptomeningeal disease;

3. Any progressive brain lesion between the brain local treatment completion and the enrolment;

4. Poorly controlled seizures (more than 1/week);

5. Clinically significant cardiopulmonary disease;

6. Used of a strong cytochrome P450 (CYP)2C8 inhibitor within 5 half-lives of the inhibitor, or use of a strong CYP3A4 or CYP2C8 inducer within 5 days prior to first dose of study treatment. Use of sensitive CYP3A substrates should be avoided one week before enrollment and during study treatment

7. Previous treatment with a tyrosine kinase inhibitor;

8. Carriers of Hepatitis B or Hepatitis C or have other known chronic liver disease;

9. Positive for human immunodeficiency virus (HIV);

10. Known prior severe hypersensitivity to tucatinib or compounds chemically or/and biologically similar or any component in its formulation;

11. History of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix) unless the patient has been in remission and off all other cancer therapy for at least 3 years;

12. Pregnant women or women who are breast-feeding;

13. Inability to swallow tablets or significant gastrointestinal disease which would preclude the adequate oral absorption of medications;

14. Person deprived of their liberty or under protective custody or guardianship or unable to give informed consent;

15. Participation in another therapeutic trial within the 30 days prior to tucatinib treatment initiation.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Seagen Inc.

INDUSTRY

Sponsor Role: collaborator

ARCAGY/ GINECO GROUP

OTHER

Sponsor Role: collaborator

UNICANCER

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Thomas Bachelot, MD

Role: PRINCIPAL_INVESTIGATOR

Centre Leon Berard

Anne-Claire Hardy-Bessard, MD

Role: PRINCIPAL_INVESTIGATOR

Centre Armoricain d'Oncologie

Locations

Institut de Cancérologie de l'Ouest - Site Paul Papin

Angers, , France

Institut Bergonié

Bordeaux, , France

Centre Francois Baclesse

Caen, , France

Centre Georges François Leclerc

Dijon, , France

Clinique Victor Hugo

Le Mans, , France

Centre Leon Berard

Lyon, , France

Hôpital privé Jean Mermoz

Lyon, , France

Institut du cancer de Montpellier

Montpellier, , France

Centre Antoine Lacassagne

Nice, , France

CARIO - Centre Armoricain Radiothérapie Imagerie Médicale et Oncologi

Plérin, , France

Centre Hospitalier Annecy Genevois

Pringy, , France

Institut Jean Godinot

Reims, , France

Centre Henri Becquerel

Rouen, , France

Institut Claudius Regaud

Toulouse, , France

Centre Hospitalier Universitaire de Tours

Tours, , France

Gustave Roussy

Villejuif, , France

Countries

France

Other Identifiers

UC-BCG-2011

Identifier Type: -

Identifier Source: org_study_id

2020-005735-79

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id